Table II.
Use of medications at follow-up
| Medications | < 130/80 mm Hg (n = 366) | < 140/90 mm Hg (n = 570) | ≥ 140/90 mm Hg (n = 290) |
|---|---|---|---|
| Antiplatelet, n (%) | 185 (50.5) | 293 (51.4) | 166 (57.2)* |
| Statins, n (%) | 168 (45.9) | 285 (50) | 163 (56.2)* |
| ACEI/ARB, n (%) | 282 (77) | 456 (80) | 243 (83.8)* |
| β-Blocker, n (%) | 103 (28.1) | 166 (29.1) | 120 (41.4)* |
| Calcium channel blocker, n (%) | 115 (31.4) | 160 (28.1) | 112 (38.6)* |
| Diuretic, n (%) | 70 (19.1) | 105 (18.4) | 95 (32.8)* |
| Number of anti-hypertensive drugs | 2.3 ±0.6 | 2.5 ±0.5 | 2.9 ±0.7* |
| Oral hypoglycemic drugs, n (%) | 96 (26.2) | 178 (31.2) | 89 (30.7) |
| Insulin, n (%) | 23 (6.3) | 30 (5.3) | 20 (6.9) |
| Blood pressure at follow-up [mm Hg]: | |||
| Systolic blood pressure | 122 ±6 | 131 ±8 | 150 ±7* |
| Diastolic blood pressure | 70 ±8 | 82 ±6 | 95 ±5* |
*
P < 0.05 vs. < 130/80 mm Hg group;
ACEI/ARB – angiotensin converting enzyme inhibitor/angiotensin receptor blocker.